Lujian Biological

Lujian Biological is a clinical-stage biopharmaceutical company headquartered in Hainan, China, with a primary focus on developing next-generation peptide therapeutics for metabolic disorders. The company's research and development efforts are centered on multi-receptor agonists, specifically targeting the GLP-1, GIP, and glucagon receptors to treat obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH). Its lead candidate, LJ-101, is a triple agonist designed for potent weight reduction and metabolic improvement. Lujian aims to address the global burden of metabolic disease through optimized peptide engineering and innovative drug design. The company is backed by prominent venture capital firms and maintains research facilities in Shanghai to support its growing pipeline.